Single center, dose escalating, safety, tolerability, and pharmacokinetic study of QR-333 in subjects with diabetic peripheral neuropathy

Trial Profile

Single center, dose escalating, safety, tolerability, and pharmacokinetic study of QR-333 in subjects with diabetic peripheral neuropathy

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2006

At a glance

  • Drugs QR 333 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Pharmacokinetics
  • Sponsors The Quigley Corporation
  • Most Recent Events

    • 26 Sep 2006 Results have been reported.
    • 20 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top